-- CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:
We raise our 12-month price target to $330 from $320, based on a 10.9x multiple of our 2026 EPS estimate, near CI's five-year historical forward average of 11.2x. We think CI's multiple balances pharmaceutical business momentum in CI's Evernorth segment and a timely portfolio shift toward more commercial exposure, offset by near-term challenges around higher medical costs across the managed care space. We raise our 2026 EPS estimate by $0.01 to $30.35 and lower 2027's by $0.09 to $33.42. Following Q1 results that beat consensus views, CI's annual Medical Care Ratio (MCR) guidance was maintained at 83.7% to 84.7% for 2026, suggesting cost discipline within a challenging operating environment for managed care. The company plans to exit the Individual ACA Exchange market by year-end 2026, citing the relatively small exposure relative to other parts of CI's portfolio and challenges with meaningfully scaling operations.